Stem Cell Treatment — How It Works, Benefits & Recovery — Procedure Guide, Recovery & Risks | MyMedicPlus

Stem cell treatment encompasses a broad category of medical therapies that use stem cells — undifferentiated cells with the capacity for self-renewal and the ability to differentiate into specialised cell types — to repair, replace, or regenerate damaged or diseased tissues. The field spans well-established, rigorously proven treatments (haematopoietic stem cell transplantation for blood cancers) through to emerging and experimental therapies under clinical trial evaluation.

Several classes of stem cells are used clinically: haematopoietic stem cells (HSCs) — blood-forming cells harvested from bone marrow, peripheral blood (after G-CSF mobilisation), or umbilical cord blood — are the most clinically established, forming the basis of bone marrow transplantation for haematological malignancies and inherited blood disorders. Mesenchymal stem cells (MSCs) — multipotent stromal cells derived from bone marrow, adipose tissue, or Wharton's jelly — have immunomodulatory and regenerative properties under clinical investigation for conditions including graft-versus-host disease, osteoarthritis, and inflammatory bowel disease.

The term 'stem cell therapy' is unfortunately also applied by unregulated private clinics to unproven treatments sold to patients with cancer, neurological conditions, or orthopaedic pain, often at significant financial and medical risk. Patients must carefully distinguish between evidence-based, approved stem cell treatments offered by regulated medical institutions and unproven commercial 'stem cell tourism' offerings without clinical trial evidence.

Proven and approved stem cell treatments are indicated for specific conditions with high-quality evidence. Haematopoietic stem cell transplantation is indicated for: acute myeloid leukaemia (AML) and acute lymphoblastic leukaemia (ALL) in remission; chronic myeloid leukaemia (CML) not responding to tyrosine kinase inhibitors; myelodysplastic syndrome (MDS) in high-risk categories; non-Hodgkin and Hodgkin lymphoma relapsed or refractory to chemotherapy; multiple myeloma (autologous transplant as standard consolidation); severe aplastic anaemia; inherited blood disorders (sickle cell disease, thalassaemia) in selected younger patients; and primary immunodeficiency disorders.

Chimeric antigen receptor T-cell (CAR-T) therapy — an advanced form of cellular therapy using genetically modified T-cells engineered to recognise cancer antigens — is approved for specific relapsed or refractory haematological malignancies including B-cell ALL, diffuse large B-cell lymphoma, multiple myeloma, and mantle cell lymphoma.

MSC therapy for graft-versus-host disease (GvHD) after allogeneic stem cell transplant is approved in several jurisdictions (Prochymal in Canada, Remestemcel-L in paediatric acute GvHD).

Haematopoietic stem cell transplantation involves three broad phases:

1. Conditioning: the patient undergoes high-dose chemotherapy (myeloablative) or reduced-intensity conditioning to destroy malignant cells and suppress the immune system, creating space in the bone marrow for donor cells. Myeloablative conditioning uses high-dose busulfan and cyclophosphamide or total body irradiation (TBI). Reduced-intensity conditioning (RIC) uses lower-dose chemotherapy, making transplant feasible in older or frailer patients.

1. Stem cell infusion: donor stem cells (allogeneic — from a matched sibling, unrelated donor, or cord blood; or autologous — the patient's own cells collected before conditioning) are infused intravenously through a central venous catheter. The infusion itself resembles a blood transfusion. Stem cells migrate to the bone marrow and begin engraftment.

1. Engraftment and recovery: neutrophil engraftment (ANC greater than 0.5 × 10^9/L for 3 consecutive days) typically occurs at days 10–21 post-infusion for peripheral blood stem cells, and 21–28 days for bone marrow or cord blood. The patient remains in a protective environment during the profound neutropenic phase.

Autologous transplant: the patient's own HSCs are collected by apheresis after G-CSF mobilisation, cryopreserved, and reinfused after myeloablative chemotherapy. No immunosuppression is required. Used for myeloma, lymphoma, and selected solid tumours. The stem cell infusion is delivered through a central venous catheter and resembles a blood transfusion. Engraftment monitoring (neutrophil count, chimerism) is performed from day 7 onward.

For haematological malignancies, stem cell transplantation offers the only curative option for many patients. Allogeneic transplantation for AML in first complete remission achieves 5-year overall survival of 50–70% in intermediate and high-risk cytogenetic groups, compared to 30–40% with chemotherapy alone. For CML refractory to tyrosine kinase inhibitors, allogeneic transplant remains curative in 50–70% of cases. Multiple myeloma patients receiving autologous transplant plus novel agents (lenalidomide maintenance) achieve a median progression-free survival of 5–7 years — significantly better than without transplant.

CAR-T cell therapy has transformed the prognosis of relapsed/refractory B-cell ALL in children and young adults, achieving complete remission in 70–90% of patients who previously had no options, with 12-month disease-free survival of 50–60%.

For sickle cell disease, allogeneic stem cell transplantation from a matched sibling donor is potentially curative in children, with event-free survival exceeding 85%. Gene therapy using autologous modified haematopoietic stem cells (Zynteglo for beta-thalassaemia, Casgevy for sickle cell disease) represents the next generation of stem cell-based cures.

Haematopoietic stem cell transplantation carries significant risks reflecting its intensity. Transplant-related mortality (TRM) from non-relapse causes is 10–20% for allogeneic transplants at 1 year, driven primarily by infections during immune deficiency, graft-versus-host disease, and organ toxicity from conditioning.

Graft-versus-host disease (GvHD) — where donor T-cells attack host tissues — is the principal allogeneic complication. Acute GvHD (within 100 days) affects 30–60% of recipients and involves skin rash, diarrhoea, and liver inflammation. Chronic GvHD (after 100 days) is a multi-organ autoimmune syndrome affecting 30–50% of long-term survivors, causing significant morbidity including sicca syndrome, lung disease, and joint contractures.

Infections — bacterial, fungal (invasive aspergillosis, candida), and viral (CMV reactivation, EBV, adenovirus) — are the leading cause of non-relapse mortality. Veno-occlusive disease (VOD/SOS) of the liver from conditioning toxicity occurs in 5–15% and can be life-threatening. Secondary malignancy risk (particularly post-transplant lymphoproliferative disease, PTLD) is elevated. For autologous transplant, TRM is lower (1–2%) but relapse risk is higher.

Recovery after haematopoietic stem cell transplantation is prolonged and complex. The initial inpatient phase lasts 3–6 weeks until neutrophil engraftment, during which the patient is at extreme infection risk and requires reverse barrier nursing, broad-spectrum IV antibiotics, antifungal prophylaxis, and antiviral therapy. Blood transfusions and platelet transfusions are required until the marrow recovers.

After discharge, outpatient monitoring continues intensively for the first 3–6 months. Immune reconstitution — rebuilding a fully functional immune system — takes 12–24 months. Re-vaccination against childhood vaccines is required at 12–24 months post-transplant as prior immunity is ablated by conditioning. Patients must avoid crowded places, raw food, and soil during immune reconstitution.

For allogeneic recipients, graft-versus-host disease (GvHD) immunosuppression (ciclosporin, tacrolimus, methotrexate) is taken for 6–24 months post-transplant, with slow tapering as immune reconstitution progresses. Return to work or education may occur at 6–12 months depending on overall recovery and ongoing treatment needs.